All In Biotech

Drug Trial Radar · NCT05952869

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia.

Last checked: Nov 20, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 303 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

303

Actual

Start

Aug 8, 2023

Primary completion

Apr 7, 2025

Study completion Apr 7, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with heterozygous familial hypercholesterolemia. The primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.

Conditions

  • Hypercholesterolemia
  • Familial Hypercholesterolemia

Interventions

  • Enlicitide DecanoateDrug

    Oral tablet

  • PlaceboDrug

    Oral tablet (placebo).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24Time frame: Baseline and Week 24
  2. Number of Participants With Adverse Events (AEs)Time frame: Up to 64 weeks (8 weeks postdose)
  3. Number of Participants Who Discontinued Study Drug Due to an AETime frame: Up to 56 weeks

Locations

59 sites in 17 countries. Site status is shown where the registry gives one.

  • Alliance for Multispecialty Research, LLC ( Site 0023)

    Daphne, Alabama

  • Excel Medical Clinical Trials ( Site 0008)

    Boca Raton, Florida

  • Advanced Pharma Research ( Site 0007)

    Cutler Bay, Florida

  • Progressive Medical Research ( Site 0021)

    Port Orange, Florida

  • Clinical Site Partners LLC, dba CSP Orlando ( Site 0028)

    Winter Park, Florida

  • Synexus Clinical Research US - Evansville ( Site 0031)

    Evansville, Indiana

  • Franciscan Physician Network - Indiana Heart Physicians ( Site 0040)

    Indianapolis, Indiana

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0001)

    Troy, Michigan

  • Velocity Clinical Research at The Pioneer Heart Institute, Lincoln ( Site 0026)

    Lincoln, Nebraska

  • Jubilee Clinical Research ( Site 0030)

    Las Vegas, Nevada

  • Wake Forest Baptist Health-Cardiovascular Medicine ( Site 0041)

    Winston-Salem, North Carolina

  • Velocity Clinical Research, Salt Lake City ( Site 0004)

    West Jordan, Utah

  • Health Research of Hampton Roads, Inc. ( Site 0020)

    Newport News, Virginia

  • Royal Prince Alfred Hospital-6West CV Ambulatory Care ( Site 2808)

    Camperdown, New South Wales, Australia

  • Victorian Heart Hospital-Monash Cardiovascular Research Centre (MCRC) ( Site 2803)

    Clayton, Victoria, Australia

  • Incor - Instituto do Coracao ( Site 0703)

    São Paulo, Brazil

  • Universidade Federal Do Ceara ( Site 0702)

    Fortaleza, Ceará, Brazil

  • Instituto Dante Pazzanese de Cardiology-Fundação Adib Jatene ( Site 0701)

    São Paulo, São Paulo, Brazil

  • Ecogene-21 ( Site 0510)

    Chicoutimi, Quebec, Canada

  • Institut de Cardiologie de Montreal ( Site 0506)

    Montreal, Quebec, Canada

  • Diex Recherche Trois-Rivieres ( Site 0513)

    Trois-Rivières, Quebec, Canada

  • Clinical Research Chile SpA ( Site 0804)

    Valdivia, Los Ríos Region, Chile

  • CDIEM ( Site 0814)

    Providencia, Region M. de Santiago, Chile

  • Enroll SpA ( Site 0803)

    Santiago, Region M. de Santiago, Chile

  • Pontificia Universidad Catolica de Chile-CICUC ( Site 0812)

    Santiago, Region M. de Santiago, Chile

  • Fundación Centro de Investigación Clínica CIC ( Site 0906)

    Medellín, Antioquia, Colombia

  • Ciensalud Ips S A S ( Site 0903)

    Barranquilla, Atlántico, Colombia

  • Clinica de la Costa S.A.S. ( Site 0902)

    Barranquilla, Atlántico, Colombia

  • Salud SURA Calle 100 ( Site 0918)

    Bogotá, Cundinamarca, Colombia

  • Fakultní nemocnice Brno Bohunice-Interni kardiologicka klinika ( Site 3602)

    Brno, Brno-mesto, Czechia

  • Institut Klinicke a Experimentalni Mediciny ( Site 3601)

    Prague, Praha 4, Czechia

  • Fakultni Nemocnice u sv. Anny v Brne ( Site 3604)

    Brno, South Moravian, Czechia

  • Meilahden tornisairaala - Meilahti Tower Hospital ( Site 1300)

    Helsinki, Uusimaa, Finland

  • Queen Mary Hospital-Medical ( Site 3300)

    Pok Fu Lam, Hong Kong

  • Prince of Wales Hospital ( Site 3304)

    Shatin, Hong Kong

  • Semmelweis Egyetem-Városmajori Szív- és Érgyógyászati Klinika ( Site 1600)

    Budapest, Hungary

  • Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Anyagcsere Tanszék) ( Site 1601)

    Debrecen, Hungary

  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Belgyógyászati Klinika ( Site 1603)

    Szeged, Csongrád megye, Hungary

  • Shaare Zedek Medical Center ( Site 1710)

    Jerusalem, Israel

  • Hadassah Medical Center ( Site 1709)

    Jerusalem, Israel

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.